It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: face23785
It boils my blood to think how many people might've been saved if there hadn't been a politically-motivated hackjob on this drug.
Let's not forget the pharmaceutical industry is the biggest lobbying force in Congress. Not the "military-industrial complex" or the "gun lobby," it's drug companies.
Here’s some clothes from the hitpiece you used a Phage .
originally posted by: Phage
a reply to: Fallingdown
Here’s some clothes from the hitpiece you used a Phage .
That "hitpiece" is the actual study which is the topic of your thread.
originally posted by: Fallingdown
a reply to: Phage
Then you’re saying it does matter except in this instance ?
You were dismissive with the information for some reason why ?
These findings do support the recent NIH guidelines (Antiviral Therapy, 2020), indicating a potential role for hydroxychloroquine in treatment of hospitalized COVID-19 patients without co-administration of azithromycin. However, our results should be interpreted with some caution and should not be applied to patients treated outside of hospital settings. Our results also require further confirmation in prospective, randomized controlled trials that rigorously evaluate the safety, and efficacy of hydroxychloroquine therapy for COVID-19 in hospitalized patients.
originally posted by: face23785
It boils my blood to think how many people might've been saved if there hadn't been a politically-motivated hackjob on this drug.
Let's not forget the pharmaceutical industry is the biggest lobbying force in Congress. Not the "military-industrial complex" or the "gun lobby," it's drug companies.
The article says that there are 65,000 patients in Italy taking HCQ chronically and that only 20 of them have tested positive for the virus. Now, you’d want to compare that to RA and lupus patients who were not taking HCQ, but it would still be quite interesting. If it were true.
Update: here’s the answer. The number is completely fictional. As mentioned here in the comments, the president of the Italian Rheumatology Society was contacted directly and states that this number is completely wrong, that the society is monitoring 150 patients in its registry, 20 of whom are taking hydroxychloroquine. The 65,000 number is bogus.
The study also found those treated with azithromycin alone or a combination of hydroxychloroquine and azithromycin also fared slightly better than those not treated with the drugs, according to the Henry Ford data. The analysis found 22.4% of those treated only with azithromycin died, and 20.1% treated with a combination of azithromycin and hydroxychloroquine died, compared to 26.4% of patients dying who were not treated with either medication.
originally posted by: Phage
a reply to: Violater1
1) I didn't say anything about peer review, much less that it doesn't matter. The question was a straw man.
2) I was not "dismissive." I pointed out that the authors of the study themselves are well aware of its flaws.
Here, again, is what I quoted from the study which is the topic of this thread.
These findings do support the recent NIH guidelines (Antiviral Therapy, 2020), indicating a potential role for hydroxychloroquine in treatment of hospitalized COVID-19 patients without co-administration of azithromycin. However, our results should be interpreted with some caution and should not be applied to patients treated outside of hospital settings. Our results also require further confirmation in prospective, randomized controlled trials that rigorously evaluate the safety, and efficacy of hydroxychloroquine therapy for COVID-19 in hospitalized patients.
source
There have been encouraging studies on the efficacy of hydroxycholoroquine and there have been studies which are not encouraging. This study is encouraging but, as yet, no studies have been completed which meet acceptable standards; controlled, randomized, and blinded.
This study does not say hydroxycholoroquine is a cure (or a preventative). It says that its use may result in fewer deaths of hosptialized patients.
an·ec·do·tal
/ˌanəkˈdōdl/
adjective
1 (of an account) not necessarily true or reliable, because based on personal accounts rather than facts or research.
Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Hydroxychloroquine (an analogue of chloroquine) has been demonstrated to have an anti-SARS-CoV activity
The antimalarial agents, *chloroquine (CQ), amodiaquine, and mefloquine have activity against SARS-CoV and MERS-CoV in vitro [36, 38, 39]. CQ is a U.S. Food and Drug Administration (FDA)-approved antimalarial agent that is also used to treat autoimmune disease such as rheumatoid arthritis due to its anti-inflammatory effects [40]. CQ has activity against a number of viruses in vitro and in vivo including flaviviruses
Researchers say the published data and surveys may be small but already show that hydroxychloroquine doesn’t fully protect people from contracting the new virus.
This weekend, Donald Trump used his daily White House coronavirus briefings to again urge Americans to take hydroxychloroquine, an anti-malaria drug that has not been shown to be safe or effective against Covid-19.
Meanwhile, Dr Anthony Fauci, the country’s top infectious disease doctor, has repeatedly warned that there is no conclusive evidence to support using the drug. Asked whether it should be considered a treatment for Covid-19, he said on 24 March: ”The answer is no.”